Scott A. Waldman, MD, PhD, FCP, FNAI

Principal Investigator

Dr. Waldman’s career has focused on integrating basic, translational, and clinical research in transmembrane signaling to advance laboratory discovery into patients.

  • This work has produced >300 publications (h index=68, >17,000 citations) and >100 patents and patent applications
  • Discoveries have been licensed by 7 companies and have been the focus of >15 clinical trials
  • Internationally recognized leader in the field of clinical pharmacology
  • Editor-In-Chief of Clinical Pharmacology & Therapeutics, Founder and Editor of Biomarkers in Medicine, and Founder and former Deputy Editor-In-Chief of Clinical and Translational Science
  • Retired Chair of NCI Subcommittee
  • Recently (2019) retired chair of the FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee
  • Recurring member of the FDA Oncology Drugs and the Arthritis Drugs Advisory Committee
  • Past President of the American Society for Clinical Pharmacology and Therapeutics, a former Regent of the American College of Clinical Pharmacology, and the former Secretary/Treasurer of the American Board of Clinical Pharmacology
  • Institutionally, Director of the KCC Gastrointestinal (GI) Malignancies Program, the MD-PhD Program, and the Postdoctoral Training Program in Clinical Pharmacology (5T32 GM08562)
  • Chairman (tenured), Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA
  • MD, Stanford University
  • PhD, Thomas Jefferson University